In accordance with 35 U.S.C. § 287(a), the following list used in conjunction with the labeling approved by the U.S. Food and Drug Administration may be used to determine patents associated with the corresponding U.S. marketed product. Additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive, and other products not listed here may be protected by one or more patents in the U.S. and additional countries.
Patents associated with SKYTROFA® (lonapegsomatropin-tcgd) lyophilized powder for solution, for subcutaneous use: